Fig. 7
HGF-induced invasion is abrogated by TβR inhibition. a EMT scores of TCGA Bladder Cancer data set (BLCA n = 408) compared with HGF expression (left panel; R = 0.683, p = 2.3E-57), phospho c-Met expression (middle panel; R = 0.3101, p = 5.19E-9) and c-Met expression (right panel; R = 0.1538, p = 0.0018). The p value is computed by Spearman correlation coefficient test. b Kaplan–Meier curves showing probability of overall survival of bladder cancer patients with higher copy number of HGF is significantly less than those with lower level of HGF (BLCA n = 408, p = 0.0429, HR = 1.562).The p value is computed by log-rank test. c EMT scores of 21 bladder cancer cell lines defined as either epithelial (green) or mesenchymal (red). d, e Analysis of bladder tumours formed from intraluminally implanted UMUC3 cells in the absence or presence of TβR inhibitors. Treatment was started when bioluminescence intensity reached ~ 5e8 photons/sec. Mice were treated for 2 weeks and tumour volumes were measured twice a week. M = muscularis propria. d H&E staining of representative tumour samples. Daily administration of vehicle control only (control; n = 5) or A83-01 (50 mg/kg; n = 5). T-stages at end of experiment in control-treated mice indicated T3-3 mice, T2-2 mice. All A83-01 treated mice were T1. Scale bars: 4 mm. e H&E staining of representative tumour samples. Daily administration of vehicle control only (control; n = 3) or LY2157299 (80 mg/kg; n = 3). T-stages at end of experiment indicated T3-1 mice, T1-2 mice. All LY2157299 treated mice were T1. Scale bars: 50 mm
